Anti-Human TCC Monoclonal Antibody (clone aE11) -0.5 mg (CAT#: CB-P296-AB) Datasheet

Antibody

The monoclonal antibody aE11 reacts with the C9 neoantigen of the terminal complement complex (TCC). Three different activation pathways of complement are fused with the formation of C5 convertase. The cleavage of C5 by this invertase initiates the cleavage or terminal pathway. In contrast to activation pathways that require enzymatic cleavage, the terminal pathway relies on binding-induced conformational changes. The binding of C6 promotes the binding of C7, which changes the conformation of the complex. After C8 is bound, a variable number of C9 molecules associate with the C5b678 complex, which is also called the terminal complement complex (TCC). The formation of TCC causes cell lysis or can trigger a variety of cellular metabolic pathways, leading to the synthesis and release of inflammatory mediators. TCC contains neoantigens that are not present in a single natural component. -C9 neoantigen exists in both membrane-bound (MAC) and liquid phase (SC5b-9) complexes. TCC exists in normal human plasma and increases in patients with complement activation.

Infectious diseases, Nephrology